Form DEF 14A Veracyte Inc For: 24 April
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Veracyte Inc (VCYT)
The Veracyte Inc share price today is 34.33 %REPORT_CURRENCY%, view NASDAQ VCYT stock exchange data. Track the latest Veracyte Inc share price with real-time updates on VCYT stock performance including market cap, day range, 52-week range and dividend yield. Access VCYT charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
32.72
34.51
52 wk Range
22.61
50.71
Earnings results expected in 9 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
32.7234.51
52 wk Range
22.6150.71
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VCYT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
46.55
Upside
+35.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
7 analysts have revised their earnings upwards for the upcoming period
- Form DEF 14A VERACYTE For: 22 April
- Investing.com
- Veracyte Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form DEF 14A Veracyte Inc For: 24 April
- Investing.com
- Form DEF 14A VERACYTE For: 22 April
- Investing.com
- Veracyte Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Veracyte Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte Inc Earnings Call Summary for Q4/2025
- Veracyte Q4 2025 EPS of $0.53 beat forecasts by 35.9%; revenue of $141M exceeded estimates by 6.17%, growing 19% year-over-year.
- Non-GAAP gross margin improved to 75.1%, up 580 basis points from prior year, driven by operational efficiencies and platform optimization.
- Afirma and Decipher platforms drove growth with increased test volumes; company generated $52.6M in operating cash flow during Q4.
- Q1 2026 revenue guidance set at $130.59M; full-year EPS forecast ranges from $0.34 to $0.45 per quarter for upcoming periods.
- Stock rose 0.08% to $35.7 post-earnings; CEO emphasized successful v2 transcriptome platform transition and continued investment in product development.
Last Updated: 26-02-2026, 04:22 am
Read Full TranscriptCompare VCYT to Peers and Sector
Metrics to compare | VCYT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVCYTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 41.1x | 7.8x | −0.4x | |
PEG Ratio | 0.25 | −0.34 | 0.00 | |
Price/Book | 2.1x | 1.6x | 2.6x | |
Price / LTM Sales | 5.3x | 2.6x | 3.2x | |
Upside (Analyst Target) | 39.8% | 44.9% | 46.2% | |
Fair Value Upside | Unlock | 1.7% | 7.2% | Unlock |
Analyst Ratings
10 Buy
1 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 46.55
(+35.58% Upside)
Earnings
Latest Release
25-02-2026
EPS / Forecast
0.53 / 0.39
Revenue / Forecast
140.6M / 132.43M
FAQ
What Is the Veracyte Inc (VCYT) Share Price Today?
The Veracyte Inc share price today is 34.33 USD.
What is the current Veracyte Inc (VCYT) share price and day range?
As of 26-04-2026, the Veracyte Inc share price is 34.33 USD, with a previous close of 33.15 USD. The share price has ranged from 32.72 to 34.51 USD today, while the 52-week range spans from 22.61 to 50.71 USD.
What Is the Veracyte Inc Market Cap?
As of today, Veracyte Inc market cap is 2.73B.
What Is the Veracyte Inc (VCYT) Share Price Target?
The average 12-month share price target for Veracyte Inc is 46.55 USD, with a high estimate of 53 USD and a low estimate of 37 USD. 10 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +35.58% Upside potential.
What Is Veracyte Inc's Earnings Per Share (TTM)?
The Veracyte Inc EPS (TTM) is 0.82.
When Is the Next Veracyte Inc Earnings Date?
Veracyte Inc will release its next earnings report on 05-05-2026.
From a Technical Analysis Perspective, Is VCYT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Veracyte Inc Trade On?
Veracyte Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Veracyte Inc?
The stock symbol for Veracyte Inc is "VCYT."
How Many Times Has Veracyte Inc Stock Split?
Veracyte Inc has split 0 times.
How Many Employees Does Veracyte Inc Have?
Veracyte Inc has 755 employees.
What Is the VCYT Premarket Price?
VCYT's last pre-market stock price is 33.25 USD. The pre-market share volume is 750.00, and the stock has changed by 0.10 USD, or 0.30%.
What Is the VCYT After Hours Price?
VCYT's last after hours stock price is 34.27 USD, the stock has changed by -0.06 USD, or -0.17%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.